Comparative effectiveness of infliximab versus adalimumab in patients with biological naïve Crohn’s Disease

dc.contributor.author	Benmassaoud A
dc.contributor.author	Al-Taweel T
dc.contributor.author	Sasson MS
dc.contributor.author	Moza D
dc.contributor.author	Strohl M
dc.contributor.author	Kopylov U
dc.contributor.author	Paradis-Suprenant L
dc.contributor.author	Almaimani M
dc.contributor.author	Bitton A Afif W
dc.contributor.author	Lakatos, Péter László
dc.contributor.author	Bessissow T
dc.date.accessioned	2019-07-11T07:23:23Z
dc.date.available	2019-07-11T07:23:23Z
dc.date.issued	2018
dc.identifier	85038108116
dc.identifier.citation	journalVolume=63;journalIssueNumber=5;journalTitle=DIGESTIVE DISEASES AND SCIENCES;pagerange=1302-1310;journalAbbreviatedTitle=DIGEST DIS SCI;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/7197
dc.identifier.uri	doi:10.1007/s10620-017-4874-6
dc.description.abstract	Direct head-to-head studies comparing the long-term outcomes of infliximab (IFX) to adalimumab (ADA) in Crohn's disease (CD) are sparse.
dc.format.extent	1302-1310
dc.relation.ispartof	urn:issn:0163-2116 1573-2568
dc.title	Comparative effectiveness of infliximab versus adalimumab in patients with biological naïve Crohn’s Disease
dc.type	Journal Article
dc.date.updated	2019-07-08T13:10:56Z
dc.language.rfc3066	en
dc.rights.holder	NULL
dc.identifier.mtmt	3316096
dc.identifier.wos	000429816400029
dc.identifier.pubmed	29243105
dc.contributor.department	SE/AOK/K/I. Sz. Belgyógyászati Klinika
dc.contributor.institution	Semmelweis Egyetem